XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa

NEXT STORY
Antibiotic Susceptibility Testing Market will Expand at 5.6% CAGR by 2028- Future Market Insights
PREV STORY
Global Vaccines Market Growth Opportunities – Forecast to 2024 by Production System, Antigens, Procurement System, and End Users
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

American Medical Association Approves New Category III CPT Codes Describing Cytori’s Scleroderma Therapy

SAN DIEGO, July 10, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today ...

author_avatar
NASDAQ Market News

Leap Therapeutics Presents Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

CAMBRIDGE, Mass., May 17, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology ...

author_avatar
NASDAQ Market News

Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference

MONT-SAINT-GUIBERT, Belgium, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a ...

author_avatar
NASDAQ Market News